KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2025)

Adaptive Biotechnologies' Share-based Compensation history spans 8 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 0.87% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $51.5 million, down 3.97%, while the annual FY2025 figure was $51.5 million, 3.97% down from the prior year.
  • Share-based Compensation for Q4 2025 was $12.7 million at Adaptive Biotechnologies, down from $13.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $17.3 million in Q2 2023 and bottomed at $8.5 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $13.3 million (2025), against an average of $13.3 million.
  • The largest annual shift saw Share-based Compensation surged 81.48% in 2021 before it dropped 25.29% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $11.9 million in 2021, then grew by 20.37% to $14.3 million in 2022, then rose by 8.83% to $15.6 million in 2023, then dropped by 17.51% to $12.8 million in 2024, then fell by 0.87% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Share-based Compensation are $12.7 million (Q4 2025), $13.3 million (Q3 2025), and $13.4 million (Q2 2025).